IVF · Quarterly Report (Form 10-Q) · Filed November 17, 2025

Invo Fertility Inc — 10-Q exhibit

ex10-1.htm

Invo Fertility Inc on Boardroom Alpha

Exhibit 10.1

November 13, 2025

James Goren

JAG Multi Investments LLC

c/o Bredefeld & Assoc. PC

125 Maple Avenue, Suite C

Chester, New Jersey 07930

RE:	Demand Notes and Warrants

Dear James

Reference is made to those certain demand notes dated October 21, October 28, November 10, December 13, December 29, 2022, and July 10, 2023 (the “Demand Notes”) issued by INVO Fertility, Inc. (f/k/a INVO Bioscience, Inc.; “INVO”) to JAG Multi Investments LLC (“JAG”). Under the Demand Notes, JAG loaned INVO a total of $600,000. All capitalized terms used herein that are not defined shall have the meaning assigned to those terms in the Demand Notes.

In a letter dated August 13, 2025 (the “August Letter”), INVO and JAG agreed to certain terms including an automatic extension of the maturity date of the Demand Notes to December 31, 2025, should INVO have paid $100,000 to JAG before September 30, 2025. To date, INVO has not made such payment.

By signing below, INVO and JAG agree to the following:

1.	Should INVO pay $100,000 to JAG before November 31, 2025, the maturity date of the Demand Notes will be extended automatically to December 31, 2025;

2.	The exercise price on the warrant issued by INVO to JAG and dated August 13, 2025 will be reduced from $2 per share to $0.75 per share; and

3.	The remaining terms of the August Letter will remain unchanged.

invofertility.com

JAG Demand Note

Page 2 of 2

Sincerely,		AGREED AND ACCEPTED BY

INVO BIOSCIENCE INC.		JAG MULTI INVESTMENTS LLC

Steve Shum, CEO		James Goren, Managing Member

invofertility.com

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer